{
    "eid": "2-s2.0-84966701371",
    "title": "Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer",
    "cover-date": "2016-08-01",
    "subject-areas": [
        {
            "$": "Oncology",
            "@code": "2730"
        },
        {
            "$": "Pulmonary and Respiratory Medicine",
            "@code": "2740"
        },
        {
            "$": "Cancer Research",
            "@code": "1306"
        }
    ],
    "keywords": [
        "Biomarkers",
        "EGFR",
        "Erlotinib",
        "NSCLC"
    ],
    "authors": [
        "Tony Mok"
    ],
    "citedby-count": 23,
    "ref-count": 27,
    "ref-list": [
        "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma",
        "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study",
        "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial",
        "National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China",
        "Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? - A literature-based meta-analysis",
        "EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital",
        "J. Thorac. Oncol.",
        "Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer",
        "Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial",
        "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib",
        "Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer",
        "Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada clinical trials group study BR.21",
        "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)",
        "Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study",
        "Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3",
        "A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies",
        "Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers",
        "High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck",
        "Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?",
        "Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy",
        "ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine",
        "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy",
        "ERCC1 isoform expression and DNA repair in non-small-cell lung cancer",
        null,
        "J. Thorac. Oncol.",
        "Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer",
        "ReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "National Taiwan University Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Manila",
            "affilname": "Philippine General Hospital",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Quezon City",
            "affilname": "Lung Center of the Philippines",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Guangzhou",
            "affilname": "Guangdong Provincial People\u2019s Hospital of Southern Medical University",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Goyang",
            "affilname": "National Cancer Center, Gyeonggi",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Chiang Mai",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "San Francisco",
            "affilname": "Genentech, Inc",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Basel",
            "affilname": "F. Hoffmann-La Roche AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Hong Kong",
            "affilname": "Chinese University of Hong Kong",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Pasig, Metro Manila",
            "affilname": "Rizal Medical Center",
            "affiliation-country": "Philippines"
        }
    ],
    "funding": [
        "Chinese Thoracic Oncology Group",
        "F. Hoffmann-La Roche"
    ]
}